text
"['\n1. 요약재무정보\n하기 연결재무정보 및 재무정보는 한국채택국제회계기준에 따라 작성되었으며,제64기 연결재무정보 및 재무정보는 주주총회 승인 전 재무제표로 향후 정기주주총회에서 재무제표 승인 관련 안건이 부결되거나 수정이 발생한 경우 정정보고서를 통해 그 내용 및 사유를 반영할 예정입니다.\n요약연결재무정보\n국제약품(주) 및 종속기업 \xa0\xa0\n(단위 : 원)\n구 분\n제64기\n제63기\n제62기\n[유동자산]\n48,197,308,387\n49,940,201,956\xa0\n61,135,035,867\xa0\n-현금및현금성자산\n7,866,062,183\n4,013,014,774\xa0\n7,448,034,125\xa0\n-매출채권\n20,652,657,728\n20,250,681,477\xa0\n20,667,104,826\xa0\n-재고자산\n16,540,406,112\n21,651,887,423\xa0\n16,595,366,817\xa0\n-기타유동자산\n3,138,182,364\n4,024,618,282\xa0\n16,424,530,099\xa0\n[비유동자산]\n91,585,738,297\xa0\n95,685,349,934\xa0\n73,458,578,230\xa0\n-유형자산\n80,044,733,529\xa0\n84,882,176,864\xa0\n64,359,978,411\xa0\n-무형자산\n1,333,272,730\xa0\n1,492,236,263\xa0\n1,677,484,748\xa0\n-투자부동산\n3,354,393,245\xa0\n3,488,952,649\xa0\n4,093,469,130\xa0\n-기타비유동자산\n6,853,338,793\xa0\n5,821,984,158\xa0\n3,327,645,941\xa0\n자산총계\n139,783,046,684\xa0\n145,625,551,890\xa0\n134,593,614,097\xa0\n[유동부채]\n54,516,684,923\xa0\n55,357,616,964\xa0\n59,250,771,507\xa0\n[비유동부채]\n16,678,553,018\xa0\n19,769,071,069\xa0\n14,388,889,463\xa0\n부채총계\n71,195,237,941\xa0\n75,126,688,033\xa0\n73,639,660,970\xa0\n[자본금]\n19,276,090,000\xa0\n18,400,520,000\xa0\n18,400,520,000\xa0\n[주식발행초과금]\n2,995,998,192\xa0\n3,871,568,192\xa0\n3,871,568,192\xa0\n[기타포괄손익누계액]\n29,430,639,780\xa0\n29,335,099,371\xa0\n21,480,876,507\xa0\n[기타자본항목]\n15,770,814,508\xa0\n15,816,353,383\xa0\n16,683,166,546\xa0\n[이익잉여금]\n1,094,519,493\xa0\n3,058,916,238\xa0\n492,983,140\xa0\n지배기업소유주지분\n68,568,061,973\xa0\n70,482,457,184\xa0\n60,929,114,385\xa0\n비지배지분\n19,746,770\xa0\n16,406,673\xa0\n24,838,742\xa0\n자본총계\n68,587,808,743\xa0\n70,498,863,857\xa0\n60,953,953,127\xa0\n부채와자본총계\n139,783,046,684\xa0\n145,625,551,890\xa0\n134,593,614,097\xa0\n매출액\n119,745,568,736\xa0\n130,394,720,787\xa0\n111,121,601,008\xa0\n영업이익(손실)\n(1,675,903,581)\n6,041,374,040\xa0\n5,570,756,961\xa0\n당기순이익(손실)\n(1,555,791,280)\n2,194,568,946\xa0\n(4,761,811,946)\n\xa01.지배기업소유주지분\n(1,559,131,377)\n2,203,001,015\xa0\n(4,760,904,168)\n\xa02.비지배지분\n3,340,097\xa0\n(8,432,069)\n(907,778)\n기타포괄손익\n(309,724,959)\n7,350,341,784\xa0\n(2,384,442,638)\n당기총포괄이익(손실)\n(1,865,516,239)\n9,544,910,730\xa0\n(7,146,254,584)\n\xa01.지배기업소유주지분\n(1,868,856,336)\n9,553,342,799\xa0\n(7,145,346,806)\n\xa02.비지배지분\n3,340,097\xa0\n(8,432,069)\n(907,778)\n주당순이익(손실)\n(85)\n120\xa0\n(259)\n연결에 포함된 회사수\n1\n1\xa0\n1\n<종속기업 재무정보 요약>\n(2021년)\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,661,479\n370,252\n4,018,304\n62,627\n(2020년) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,592,178\n307,625\n3,960,265\n(158,101)\n(2019년) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,510,709\n465,726\n2,429,926\n(17,021)\n요약재무정보\n국제약품(주) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\n(단위 : 원)\n구 분\n제64기\n제63기\n제62기\n[유동자산]\n47,509,136,962\xa0\n49,174,515,891\xa0\n60,161,878,936\xa0\n-현금및현금성자산\n7,654,384,083\xa0\n3,658,329,420\xa0\n7,218,053,324\xa0\n-매출채권\n20,228,765,209\xa0\n19,929,859,420\xa0\n20,233,344,301\xa0\n-재고자산\n16,491,918,820\xa0\n21,569,134,807\xa0\n16,296,426,007\xa0\n-기타유동자산\n3,134,068,850\xa0\n4,017,192,244\xa0\n16,414,055,304\xa0\n[비유동자산]\n90,628,761,663\xa0\n94,837,294,329\xa0\n72,940,313,200\xa0\n-유형자산\n79,572,383,576\xa0\n84,465,524,125\xa0\n64,214,202,193\xa0\n-무형자산\n1,271,874,285\xa0\n1,489,062,824\xa0\n1,674,311,309\xa0\n-투자부동산\n3,453,461,341\xa0\n3,592,170,673\xa0\n4,093,469,130\xa0\n-기타비유동자산\n6,331,042,461\xa0\n5,290,536,707\xa0\n2,958,330,568\xa0\n자산총계\n138,137,898,625\xa0\n144,011,810,220\xa0\n133,102,192,136\xa0\n[유동부채]\n54,321,860,051\xa0\n55,168,831,048\xa0\n59,080,611,261\xa0\n[비유동부채]\n16,314,880,710\xa0\n19,415,080,745\xa0\n14,278,918,866\xa0\n부채총계\n70,636,740,761\xa0\n74,583,911,793\xa0\n73,359,530,127\xa0\n[자본금]\n19,276,090,000\xa0\n18,400,520,000\xa0\n18,400,520,000\xa0\n[주식발행초과금]\n2,995,998,192\xa0\n3,871,568,192\xa0\n3,871,568,192\xa0\n[기타포괄손익누계액]\n29,308,727,106\xa0\n29,236,392,939\xa0\n21,480,876,507\xa0\n[기타자본항목]\n15,944,158,435\xa0\n15,989,697,310\xa0\n16,856,510,473\xa0\n[이익잉여금]\n(23,815,869)\n1,929,719,986\xa0\n(866,813,163)\n자본총계\n67,501,157,864\xa0\n69,427,898,427\xa0\n59,742,662,009\xa0\n자본과부채총계\n138,137,898,625\xa0\n144,011,810,220\xa0\n133,102,192,136\xa0\n종속·관계·공동기업\n투자주식의 평가방법\n원가법\n원가법\n원가법\n매출액\n115,744,739,600\xa0\n126,514,615,485\xa0\n108,709,297,057\xa0\n영업이익(손실)\n(1,747,037,562)\n6,195,143,340\xa0\n5,594,782,551\xa0\n당기순이익(손실)\n(1,548,270,487)\n2,433,601,066\xa0\n(4,987,038,125)\n기타포괄손익\n(332,931,201)\n7,251,635,352\xa0\n(2,384,442,638)\n당기총포괄손익\n(1,881,201,688)\n9,685,236,418\xa0\n(7,371,480,763)\n주당순이익(손실)\n(84)\n132\n(271)\n']"
